Atrium Therapeutics, Inc. (RNA)
NASDAQ:RNA
Want to see RNA full AI Analyst Report?
Top Page
Atrium Therapeutics, Inc.
(NASDAQ:RNA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$12.50
▼(-13.25% Downside)
Action:N/A
Date:06/17/26
The score is primarily constrained by very weak financial performance—large ongoing losses and significant negative free cash flow—despite rapid revenue growth. Technical indicators are neutral-to-soft (negative MACD and below the 50-day average), and valuation support is limited given a negative P/E and no dividend.
Positive Factors
Revenue Growth
Sustained ~96% YoY revenue growth shows the company is materially expanding top-line throughput and market traction. Over 2–6 months this indicates improving product adoption or commercial execution, providing a foundation to leverage operating scale toward future margin improvement if costs are controlled.
Negative Factors
Cash Burn
Very large negative operating cash flow and free cash flow represent structural cash burn that will require recurring financing unless reversed. Over the next several months this creates persistent funding pressure, dilutive financing risk, and constrains ability to invest without external capital or major cost reduction.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~96% YoY revenue growth shows the company is materially expanding top-line throughput and market traction. Over 2–6 months this indicates improving product adoption or commercial execution, providing a foundation to leverage operating scale toward future margin improvement if costs are controlled.
Read all positive factors
Atrium Therapeutics, Inc. (RNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$216.56M
Dividend YieldN/A
Average Volume (3M)2.09M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees511
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,105,642
10 Day Avg. Volume2,820,857
30 Day Avg. Volume2,094,181
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)13.56
P/FCF Ratio-5.93
Enterprise Value/Market Cap-0.24
Enterprise Value/Revenue-1.40
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$25.00Price Target Upside73.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atrium Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently...
Atrium Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.82M | 18.62M | 10.90M | 9.56M | 9.22M | 9.33M |
| Gross Profit | -101.46M | 18.62M | 10.90M | 7.46M | 7.84M | -91.86M |
| EBITDA | -408.11M | -76.50M | -376.16M | -233.50M | -177.53M | -117.41M |
| Net Income | -396.46M | -76.68M | -322.30M | -212.22M | -174.00M | -118.01M |
Balance Sheet | ||||||
| Total Assets | 292.36M | 278.35M | 1.56B | 628.55M | 638.80M | 427.58M |
| Cash, Cash Equivalents and Short-Term Investments | 267.85M | 270.00M | 1.50B | 595.35M | 610.73M | 405.54M |
| Total Debt | 2.68M | 3.67M | 6.80M | 9.85M | 10.69M | 11.73M |
| Total Liabilities | 58.26M | 71.07M | 138.94M | 127.79M | 60.73M | 46.15M |
| Stockholders Equity | 234.10M | 207.29M | 1.42B | 500.76M | 578.08M | 381.43M |
Cash Flow | ||||||
| Free Cash Flow | -416.44M | -42.57M | -307.94M | -123.29M | -139.09M | -98.55M |
| Operating Cash Flow | -406.23M | -41.13M | -300.87M | -119.06M | -136.27M | -94.81M |
| Investing Cash Flow | -405.42M | -1.45M | -854.20M | -130.07M | -189.96M | -82.52M |
| Financing Cash Flow | 1.18B | 42.57M | 1.19B | 93.86M | 346.17M | 176.32M |
Atrium Therapeutics, Inc. Technical Analysis
Negative
14.41
Price Trends
Market Momentum
0.14
Positive
58.43
Neutral
29.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNA, the sentiment is Negative. The current price of 14.41 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNA.
Atrium Therapeutics, Inc. Risk Analysis
Atrium Therapeutics, Inc. disclosed 92 risk factors in its most recent earnings report. Atrium Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atrium Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $6.55B | -34.90 | 99.84% | ― | -53.34% | -130.87% | |
58 Neutral | $7.26B | -14.24 | -68.16% | ― | ― | -1.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.22B | -9.14 | -30.88% | ― | -89.11% | -37.55% | |
49 Neutral | $6.64B | -32.46 | -203.25% | ― | 58.67% | -11.45% | |
45 Neutral | $216.56M | -3.35 | -29.67% | ― | ― | ― |
* Healthcare Sector Average
RNA
Atrium Therapeutics, Inc.
12.66
-2.09
-14.17%
PTCT
PTC Therapeutics
78.98
29.38
59.23%
CRSP
Crispr Therapeutics AG
54.09
8.54
18.75%
RYTM
Rhythm Pharmaceuticals
96.79
34.66
55.79%
IMVT
Immunovant
35.34
19.87
128.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.